Ovarian Cancer May Mimic Fallopian Tube FormationMarch 07, 2007A new study suggests that ovarian cancer cells form by hijacking a developmental genetic process normally used to form fallopian tubes. Scientists at the Georgia Institute of Technology and the Ovarian Cancer Institute discovered that the protein, PAX8, is involved in the development of fallopian tubes and is present in ovarian cancer cells, but not in normal ovarian tissue. The discovery not only provides a new target for diagnostic and therapeutic interventions, but also opens new avenues for basic research in ovarian cancer pathology. The research appears in Volume 104, Issue 3 of the journal Gynecologic Oncology. "Our finding sustains the promise of a molecular genetic understanding of different cancers and emphasizes the importance of describing cancer in the context of normal human development that has gone awry due to genetic and epigenetic alterations," said Nathan Bowen, Georgia Cancer Coalition Distinguished Cancer Scientist at Georgia Tech and the Ovarian Cancer Institute (OCI). Using cancerous and non-cancerous tissue straight from the operating room, Bowen and fellow OCI researchers are engaged in investigating the molecular profile of ovarian cancer tissue in order to discover the causes of ovarian cancer, develop a reliable diagnostic blood test and understand the genetic basis of resistance to chemotherapy. In 2003, a group from Stanford University researching breast cancer discovered that paired box gene 8 is expressed in ovarian cancer tissue, but not in breast cancer. Taking note of the Stanford group's results, OCI researchers began to investigate the possibility that the gene and its products may be an important biomarker for detecting and researching the causes of ovarian cancer. They began to look for evidence of PAX8, the protein made by paired box gene 8, which was the next step in establishing the gene as a biomarker. Not only did they find PAX8 in the ovarian cancer cells, but they also found it in the cells that form fallopian tubes, the secretory cells. In addition, they discovered that the protein is not expressed in the normal ovarian surface epithelium. Bowen proposes that ovarian cancer begins by using PAX8 to direct an adult stem cell population found on the ovarian surface to proliferate and ultimately form ovarian cancer. When this gene is turned on in an embryo, it leads to the development of fallopian tubes. When the gene is expressed in healthy adult ovarian cells that migrate into the body of the ovary, it leads to the development of ovarian inclusion cysts. Normally, the growth of cysts is kept in check by the cells' feedback mechanisms that turn off cell growth. But in cancer, when these feedback mechanisms are mutated, the cysts grow out of control until they metastasize. "It's a way of molecularly characterizing tumors that may lead to designing specific therapies based on the molecular profile," said Bowen. "Biology is basically an information processing system to generate end products, and there are a lot of decisions that have to be made by the regulatory genes, like paired box gene 8, before the end products can be made. Bowen's next steps are to find out why paired box gene 8 gets turned on and to discover its targets in order to find out of it turns on another decision-making gene or an endpoint gene. \\\ The Ovarian Cancer Institute |
|||||||||||||||||||||
| Related Ovarian Cancer Current Events and Ovarian Cancer News Articles FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible. Metals could forge new cancer drug Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds. Breast cancer patients with high risk gene diagnosed 6 years earlier than generation before Women with a deleterious gene mutation are diagnosed with breast cancer six years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas M. D. Anderson Cancer Center. Cancer Predisposition From Gene Variant Shows Strong Gender Bias Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated. Medications Effective in Reducing Risks for Breast Cancer Can Also Cause Serious Side Effects Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health & Human Services. Scientists from University of Hawaii at Manoa find genetic marker A new genetic marker associated with ovarian cancer risk was recently discovered by an international research group, led by scientists from the Cancer Research Genetic Epidemiology Unit in the United Kingdom. New treatment in sight for ovarian cancer In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells. Young early stage ovarian cancer patients can preserve fertility A new study finds that young women with early-stage ovarian cancer can preserve future fertility by keeping at least one ovary or the uterus without increasing the risk of dying from the disease. Estrogen-Dependent Switch Tempers Killing Activity of Immune Cells The sex hormone estrogen tempers the killing activity of a specific group of immune cells, the cytotoxic T cells (CTLs), which are known to attack tumor cells and cells infected by viruses. More Ovarian Cancer Current Events and Ovarian Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||